AU2017253228B2 - Nalmefene, naltrexone or derivatives thereof for use in treating (non)-alcoholic steatohepatitis or non-alcoholic fatty liver disease - Google Patents

Nalmefene, naltrexone or derivatives thereof for use in treating (non)-alcoholic steatohepatitis or non-alcoholic fatty liver disease Download PDF

Info

Publication number
AU2017253228B2
AU2017253228B2 AU2017253228A AU2017253228A AU2017253228B2 AU 2017253228 B2 AU2017253228 B2 AU 2017253228B2 AU 2017253228 A AU2017253228 A AU 2017253228A AU 2017253228 A AU2017253228 A AU 2017253228A AU 2017253228 B2 AU2017253228 B2 AU 2017253228B2
Authority
AU
Australia
Prior art keywords
compound
nash
nafld
formula
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017253228A
Other languages
English (en)
Other versions
AU2017253228A8 (en
AU2017253228A1 (en
Inventor
Peter J. S. Chiu
May Mei-Chi Hsu
Edwin S. C. Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TaiwanJ Pharmaceuticals Co Ltd
Original Assignee
TaiwanJ Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TaiwanJ Pharmaceuticals Co Ltd filed Critical TaiwanJ Pharmaceuticals Co Ltd
Publication of AU2017253228A1 publication Critical patent/AU2017253228A1/en
Publication of AU2017253228A8 publication Critical patent/AU2017253228A8/en
Application granted granted Critical
Publication of AU2017253228B2 publication Critical patent/AU2017253228B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2017253228A 2016-04-22 2017-04-20 Nalmefene, naltrexone or derivatives thereof for use in treating (non)-alcoholic steatohepatitis or non-alcoholic fatty liver disease Active AU2017253228B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662326435P 2016-04-22 2016-04-22
US62/326,435 2016-04-22
US201662395436P 2016-09-16 2016-09-16
US62/395,436 2016-09-16
PCT/US2017/028529 WO2017184819A1 (en) 2016-04-22 2017-04-20 Nalmefene, naltrexone or derivatives thereof for use in treating (non)-alcoholic steatohepatitis or non-alcoholic fatty liver disease

Publications (3)

Publication Number Publication Date
AU2017253228A1 AU2017253228A1 (en) 2018-09-27
AU2017253228A8 AU2017253228A8 (en) 2019-01-17
AU2017253228B2 true AU2017253228B2 (en) 2020-04-09

Family

ID=58668969

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017253228A Active AU2017253228B2 (en) 2016-04-22 2017-04-20 Nalmefene, naltrexone or derivatives thereof for use in treating (non)-alcoholic steatohepatitis or non-alcoholic fatty liver disease

Country Status (10)

Country Link
US (1) US10045977B2 (cg-RX-API-DMAC7.html)
EP (1) EP3445363A1 (cg-RX-API-DMAC7.html)
JP (1) JP2019514872A (cg-RX-API-DMAC7.html)
KR (1) KR20180129909A (cg-RX-API-DMAC7.html)
CN (2) CN117137917A (cg-RX-API-DMAC7.html)
AU (1) AU2017253228B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018071705A2 (cg-RX-API-DMAC7.html)
CA (1) CA3021788C (cg-RX-API-DMAC7.html)
RU (1) RU2717677C1 (cg-RX-API-DMAC7.html)
WO (1) WO2017184819A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
ES2860423T3 (es) 2014-05-28 2021-10-05 Childrens Hospital Med Ct Métodos y sistemas para convertir células precursoras en tejidos gástricos mediante diferenciación dirigida
WO2016061464A1 (en) 2014-10-17 2016-04-21 Children's Hospital Center, D/B/A Cincinnati Children's Hospital Medical Center In vivo model of human small intetine using pluripotent stem cells and methods of making and using same
JP6963882B2 (ja) 2016-05-05 2021-11-10 チルドレンズ ホスピタル メディカル センター 胃底部組織のインビトロでの製造のための方法及び当該方法と関連した組成物
CN109475626A (zh) * 2016-07-14 2019-03-15 儿童医院医疗中心 治疗纤维化的方法
EP3534907A4 (en) 2016-11-04 2020-06-24 Children's Hospital Medical Center COMPOSITIONS AND METHODS FOR TREATING HEPATIC DISEASE
EP3548507A4 (en) 2016-12-05 2020-07-15 Children's Hospital Medical Center COLON ORGANOIDS AND PROCESSES FOR THE PREPARATION AND USE THEREOF
EP3609997A4 (en) 2017-04-14 2021-03-03 Children's Hospital Medical Center COMPOSITIONS OF STEM CELLS FROM MULTIPLE DONOR CELLS AND THEIR PREPARATION PROCEDURES
CA3077442A1 (en) 2017-10-10 2019-04-18 Children's Hospital Medical Center Esophageal tissue and/or organoid compositions and methods of making same
WO2019126626A1 (en) 2017-12-21 2019-06-27 Children's Hospital Medical Center Digitalized human organoids and methods of using same
SG11202100533VA (en) 2018-07-26 2021-02-25 Childrens Hospital Med Ct Hepato-biliary-pancreatic tissues and methods of making same
CA3112026A1 (en) 2018-09-12 2020-03-19 Children's Hospital Medical Center Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
US12497597B2 (en) 2019-05-31 2025-12-16 Children's Hospital Medical Center Methods of generating and expanding hematopoietic stem cells
KR20230073125A (ko) 2021-11-18 2023-05-25 (주)인벤티지랩 난용성 약물을 포함하는 마이크로 입자의 제조 방법
AU2022394933A1 (en) 2021-11-18 2024-05-09 Inventage Lab Inc. Sustained-release injectable composition containing naltrexone and method for preparing same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102048733A (zh) * 2010-12-23 2011-05-11 武汉同源药业有限公司 盐酸纳美芬的医药用途
US20150335638A1 (en) * 2009-07-16 2015-11-26 Mallinckrodt Llc (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5086058A (en) * 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
US7923454B2 (en) * 2002-05-17 2011-04-12 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
MXPA04011327A (es) 2002-05-17 2005-08-15 Jenken Biosciences Inc Opioides y compuestos similares a opioides y usos de los mismos.
US8017622B2 (en) * 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
TR201002473A2 (tr) * 2010-03-31 2011-09-21 Mustafa Nevzat �La� Sanay�� A.�. Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi.
JP6246895B2 (ja) * 2013-04-22 2017-12-13 カディラ・ヘルスケア・リミテッド 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）のための新規組成物
EP3416619A2 (en) * 2016-02-18 2018-12-26 Immune Therapeutics, Inc. Method for inducing a sustained immune response

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150335638A1 (en) * 2009-07-16 2015-11-26 Mallinckrodt Llc (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof
CN102048733A (zh) * 2010-12-23 2011-05-11 武汉同源药业有限公司 盐酸纳美芬的医药用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A. MOSLEHI ET AL, "Naltrexone attenuates endoplasmic reticulum stress induced hepatic injury in mice", ACTA PHYSIOLOGICA HUNGARICA, HU, (2014-09-01), vol. 101, no. 3, doi:10.1556/APhysiol.101.2014.3.9, ISSN 0231-424X, pages 341 - 352 *
GIOVANNI ADDOLORATO ET AL, "Management of Alcohol Dependence in Patients with Liver Disease", CNS DRUGS, AUCKLAND, NZ, (2013-03-01), vol. 27, no. 4, doi:10.1007/s40263-013-0043-4, ISSN 1172-7047, pages 287 - 299 *

Also Published As

Publication number Publication date
CN109069503A (zh) 2018-12-21
CN117137917A (zh) 2023-12-01
WO2017184819A1 (en) 2017-10-26
KR20180129909A (ko) 2018-12-05
CA3021788C (en) 2021-08-03
BR112018071705A2 (pt) 2019-02-19
RU2717677C1 (ru) 2020-03-25
AU2017253228A8 (en) 2019-01-17
AU2017253228A1 (en) 2018-09-27
EP3445363A1 (en) 2019-02-27
US20170304294A1 (en) 2017-10-26
CA3021788A1 (en) 2017-10-26
JP2019514872A (ja) 2019-06-06
US10045977B2 (en) 2018-08-14

Similar Documents

Publication Publication Date Title
AU2017253228B2 (en) Nalmefene, naltrexone or derivatives thereof for use in treating (non)-alcoholic steatohepatitis or non-alcoholic fatty liver disease
JP2019514872A5 (cg-RX-API-DMAC7.html)
AU2011230081A1 (en) Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same
US20170304224A1 (en) Method for the treatment of fatty liver disease
KR20220113411A (ko) KV7 칼륨 채널 개방제(opener)의 통증 치료를 위한 용도
JP7184805B2 (ja) 肥満症の予防のためのベタイン
JP2015501849A5 (cg-RX-API-DMAC7.html)
JP7759109B2 (ja) Ｅｏｍｅｓ陽性ＣＤ４陽性Ｔ細胞の増加に起因する進行型疾患治療剤
US20180318290A1 (en) Use of nalmefene in non-alcoholic steatohepatitis
JP2019041675A (ja) Ｎａｓｈ肝発がんモデル非ヒト動物及びその使用
KR100294329B1 (ko) 간질환 치료 및 예방용 의약 조성물
TWI710372B (zh) 用於胃輕癱之5-ht4受體激動劑
TW201813646A (zh) 納美芬(nalmefene)在非酒精性脂肪肝炎(nash)的應用
CN113813281A (zh) 肌苷在制备预防和治疗结核病药物中的应用
CN101224212A (zh) 阿魏酸及其钠盐用于制备预防和治疗抑郁症的药物
CN113368107B (zh) 包含小檗碱和苦参碱的药物组合物及其治疗或预防非酒精性脂肪性肝病的用途
KR20190130241A (ko) 크로몰린 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 지방간의 예방 또는 치료용 약학적 조성물
US20140275138A1 (en) Method and products for treating diabetes
JP7720104B2 (ja) トルセミドおよびクロモリンを含む代謝疾患予防または治療用組成物
US20240058300A1 (en) Tocotrienol compositions and methods to treat non-alcoholic steatohepatitis
KR20210020788A (ko) 하이드로퀴논 유도체, 및 오베티콜릭산을 포함하는 비알콜성 지방간염의 예방 또는 치료용 약학조성물
CN121197128A (zh) 对乙酰氨基酚与非那西丁的组合物及其应用
TW202521121A (zh) 光色素用於製備治療或改善非酒精性脂肪性肝病及肥胖症之組合物的用途
KR101541016B1 (ko) 피노카베올의 신규한 용도
CN120775005A (zh) 一种多肽组合物及其在用于治疗男性勃起功能障碍中的用途

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 32 , NO 37 , PAGE(S) 5229 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME TAIWANJ PHARMACEUTICALS CO., LTD., APPLICATION NO. 2017253228, UNDER INID (72) ADD CO-INVENTOR WU, EDWIN S. C.

FGA Letters patent sealed or granted (standard patent)